Investors

Inversago is a clinical stage biopharmaceutical company dedicated to developing therapies for patients suffering from debilitating metabolic diseases. A privately-owned company with a unique portfolio of peripherally-acting CB1 receptor (CB1r) blockers, the company completed a Series C funding in 2022 led by New Enterprise Associates (“NEA”).

Our main investors

For more information on investment opportunities, please contact us at: inversago@argotpartners.com.

Inversago Pharma benefits from the financial support of the Ministère de l’Économie et de l’Innovation du Québec